Hims & Hers Health (HIMS) to Release Quarterly Earnings on Monday

Hims & Hers Health (NYSE:HIMS) will be releasing its earnings data after the market closes on Monday, May 6th. Analysts expect Hims & Hers Health to post earnings of $0.02 per share for the quarter. Persons that are interested in registering for the company’s earnings conference call can do so using this link.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings results on Monday, February 26th. The company reported $0.01 earnings per share for the quarter, topping the consensus estimate of ($0.02) by $0.03. The company had revenue of $246.60 million for the quarter, compared to analysts’ expectations of $245.84 million. Hims & Hers Health had a negative return on equity of 7.21% and a negative net margin of 2.70%. The firm’s revenue for the quarter was up 47.4% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.05) earnings per share. On average, analysts expect Hims & Hers Health to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Hims & Hers Health Trading Up 1.9 %

Shares of Hims & Hers Health stock opened at $12.50 on Monday. The business has a fifty day simple moving average of $13.75 and a two-hundred day simple moving average of $10.10. The firm has a market capitalization of $2.68 billion, a P/E ratio of -113.64 and a beta of 0.91. Hims & Hers Health has a 12 month low of $5.65 and a 12 month high of $17.16.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the stock. Canaccord Genuity Group started coverage on shares of Hims & Hers Health in a research note on Wednesday, April 10th. They set a “buy” rating and a $20.00 price objective on the stock. Imperial Capital upgraded Hims & Hers Health from an “in-line” rating to an “outperform” rating and set a $16.00 price target on the stock in a research note on Wednesday, February 28th. Canaccord Genuity Group assumed coverage on Hims & Hers Health in a research note on Wednesday, April 10th. They set a “buy” rating and a $20.00 price objective for the company. Citigroup increased their target price on Hims & Hers Health from $12.00 to $16.00 and gave the stock a “buy” rating in a research note on Tuesday, February 27th. Finally, Leerink Partnrs reiterated a “market perform” rating on shares of Hims & Hers Health in a research note on Monday, February 26th. Five investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $14.85.

Insider Buying and Selling at Hims & Hers Health

In other news, CEO Andrew Dudum sold 50,361 shares of Hims & Hers Health stock in a transaction that occurred on Wednesday, March 20th. The shares were sold at an average price of $16.34, for a total value of $822,898.74. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other news, CEO Andrew Dudum sold 50,361 shares of the firm’s stock in a transaction on Wednesday, March 20th. The stock was sold at an average price of $16.34, for a total value of $822,898.74. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Soleil Boughton sold 4,080 shares of the company’s stock in a transaction on Friday, February 9th. The shares were sold at an average price of $10.03, for a total value of $40,922.40. Following the sale, the insider now owns 154,345 shares of the company’s stock, valued at approximately $1,548,080.35. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 533,050 shares of company stock worth $7,191,666. Company insiders own 31.63% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.